Key result
Thirty-day readmission after rectal cancer surgery was associated with an increased risk of mortality (HR 1.20; 95% CI 1.15-1.25; p < 0.001) and shorter overall survival.
Why the study?
No studies had investigated the relationship between readmission and survival in patients undergoing rectal cancer surgery.
Does 30-day readmission after rectal cancer surgery reduce overall survival in patients with rectal/rectosigmoid adenocarcinoma?
Cohort (n=110,167)
Yes
Does 30-day readmission after rectal cancer surgery reduce overall survival in patients with rectal/rectosigmoid adenocarcinoma?
Hazard Ratio: 1.2 (95% CI 1.15–1.25)
Absolute Event Rate: 58.98% vs 64.96%
p-value: p=< 0.001
Thirty-day readmission after rectal cancer surgery is associated with significantly decreased overall survival.
May indicate higher mortality risk after rectal cancer surgery; leaves open whether preventing readmissions improves survival.
BACKGROUND: Readmission has received attention as a potential healthcare quality metric. No studies have investigated the relationship between readmission and survival in patients undergoing rectal cancer surgery. The aims of this study were to identify factors associated with 30-day readmission after rectal cancer surgery and to determine the impact of readmission on overall survival (OS). METHODS: Patients who underwent surgical treatment for rectal/rectosigmoid adenocarcinoma stages I-IV were identified using the National Cancer Database (2004-2014). Multivariable logistic regression was used to identify factors for readmission. 2:1 nearest neighbor caliper matching without replacement was used to ensure similarity of patients being compared. Survival analyses were performed using Kaplan-Meier method along with log-rank test and Cox proportional hazards model. RESULTS: Of 110,167 patients, 7045 (6.39%) were readmitted. Factors associated with readmission included higher Charlson comorbidity score, non-private or no insurance, procedure type, hospitals in the Northeast, South, and Midwest regions, and prolonged length of stay. Within the matched cohort (13,756 non-readmitted and 6878 readmitted), readmitted patients had worse 5- and 10-year OS regardless of cancer stage (p < 0.001) and procedure type. Five- and 10-year OS were 58.98% and 41.01% for readmitted patients, 64.96% and 43.50% for non-readmitted patients. Readmitted patients had shorter OS by 13.14 months and increased risk of mortality (HR 1.20, 95% CI 1.15-1.25, p < 0.001). CONCLUSIONS: Thirty-day readmission after rectal cancer surgery is associated with decreased OS. Efforts to reduce readmissions should be considered to advance cancer care and enhance the potential for improved patient survival.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2019) conducted a cohort in Rectal/rectosigmoid adenocarcinoma (n=110,167). 30-day readmission vs. No 30-day readmission was evaluated on Overall survival (5-year) (HR 1.20, 95% CI 1.15-1.25, p=< 0.001). Thirty-day readmission after rectal cancer surgery was associated with an increased risk of mortality (HR 1.20; 95% CI 1.15-1.25; p < 0.001) and shorter overall survival.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: